While ESMO 2024 once again did not yield a phase III trial for brain tumours, it presented intriguing findings from early-phase clinical trials and translational studies. We highlight three of the most significant and promising trials related to brain tumours discussed at the conference, particularly focusing on IDH-mutated tumours, glioblastoma, and novel immunotherapy strategies.
(BELG J MED ONCOL 2024;18(8):337–340)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
